Allosteric modulation of G protein-coupled receptors: Perspectives and recent developments

Drug Discovery Today

Volumn 9, Issue 17, 2004, Pages 752-758

  Soudijn, Willem ^a   Van Wijngaarden, Ineke ^a   Ijzerman, Ad P ^a  

^a Leiden/Amsterdam   (Netherlands)

Author keywords

allosteric enhancer; allosteric inhibitor; allosteric modulator; Chemical Biology; Drug Discovery; Pharmaceutical Science; positive and negative cooperativity

Indexed keywords

1,6 HEXAMETHYLENEBIS[DIMETHYL(3 PHTHALIMIDOPROPYL)AMMONIUM BROMIDE]; 2 AMINO 3 (3,4 DICHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 4 METHOXY N [7 METHYL 3 (2 PYRIDINYL) 1 ISOQUINOLINYL]BENZAMIDE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; AC 42; ADENOSINE RECEPTOR; BENZALDEHYDE HYDRAZONE; CALCIUM SENSING RECEPTOR; CALHEX 231; CALINDOL; CINACALCET; CORTICOTROPIN RELEASING FACTOR RECEPTOR; DIALLYLCARACURINE V; EGLUMETAD; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR A; G PROTEIN COUPLED RECEPTOR B; G PROTEIN COUPLED RECEPTOR C; LIGAND; LY 487379; MUSCARINIC RECEPTOR; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; NORCLOZAPINE; R 12919; UNCLASSIFIED DRUG;

ALLOSTERISM; CLINICAL TRIAL; DRUG RESEARCH; DRUG TARGETING; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PROTEIN ENGINEERING; PROTEIN TARGETING; PROTEOMICS; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; REVIEW; THIOCHROME;

ALLOSTERIC REGULATION; ANIMALS; CLINICAL TRIALS; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 4344603756     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03220-9     Document Type: Review

References (37)

1. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964
2. Monod J., et al. Allosteric proteins and cellular control systems. J. Mol. Biol. 6:1963;306-329
3. Bockaert J., Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18:1999;1723-1729
4. Soudijn W., et al. Allosteric modulation of G protein-coupled receptors. Curr. Opin. Drug Discov. Devel. 5:2002;749-755
5. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1:2002;198-210
6. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54:2002;323-374
7. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38:1990;939-949
8. 1 receptor binding by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38:1990;950-958
9. 1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J. Med. Chem. 42:1999;3629-3636
10. 1 adenosine receptors. J. Med. Chem. 45:2002;382-389
11. 1 adenosine agonist binding: new 3, 4-, and 5-modifications. J. Med. Chem. 46:2003;1870-1877
12. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol. Pharmacol. 60:2001;1057-1063
13. 3 adenosine receptors by a series of imidazoquinoline derivatives. Mol. Pharmacol. 62:2002;81-89
14. 3 adenosine receptor. Mol. Pharmacol. 63:2003;1021-1031
15. 2 acetylcholine receptors. Bioorg. Med. Chem. Lett. 10:2000;2529-2532
16. Buller S., et al. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V and derivatives and alkane-bisammonium ligands. Mol. Pharmacol. 61:2002;160-168
17. 5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol. Pharmacol. 64:2003;21-31
18. Muth M., et al. Systematic development of high affinity bis(ammonio)alkyl-type enhancers of muscarinic ligand binding. J. Med. Chem. 46:2003;1031-1040
19. 4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65:2004;257-266
20. 1 muscarinic receptor. Mol. Pharmacol. 61:2002;1297-1302
21. Sur C., et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 100:2003;13674-13679
22. Stacey M., et al. LNB-TM7, a group of seven-transmembrane proteins related to family-B G-protein-coupled receptors. Trends Biochem. Sci. 25:2000;284-289
23. Hoare S.R.J., et al. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol. Pharmacol. 63:2003;751-765
24. Hoare S.R.J., et al. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry. 43:2004;3996-4011
25. Kunishima N., et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature. 407:2000;971-977
26. O'Brien J.A., et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol. 64:2003;731-740
27. Schaffhauser H., et al. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64:2003;798-810
28. Nemeth E.F., et al. Pharmacodynamics of the Type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308:2004;627-635
29. 2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J. Biol. Chem. 279:2004;18990-18997
30. Nemeth E.F. The search for calcium receptor antagonists (calcilytics). J. Mol. Endocrinol. 29:2002;15-21
31. Holsboer F. Corticotropin-releasing hormone modulators and depression. Curr. Opin. Invest. Drugs. 4:2003;46-50
32. Grillon C., et al. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl.). 168:2003;446-454
33. 2-induced panic anxiety in patients diagnosed with DSM-IV panic disorder. 42nd New Clinical Drug Evaluation Unit Meeting, 10-13 June 2002, Boca Raton, Florida, USA (Abstract I-94)
34. Holden C. Psychiatric drugs: excited by glutamate. Science. 300:2002;1866-1868
35. Goodman W.G., et al. The calcimimetic agent AMG073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. 13:2002;1017-1024
36. Block G.A., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New Engl. J. Med. 350:2004;1516-1525
37. Goudet C., et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc. Natl. Acad. Sci. U.S.A. 101:2003;378-383